胰腺导管腺癌进展的动态分子网络分析
Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression.
作者信息
Pan Zongfu, Li Lu, Fang Qilu, Zhang Yiwen, Hu Xiaoping, Qian Yangyang, Huang Ping
机构信息
1Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, 310022 China.
2Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003 China.
出版信息
Cancer Cell Int. 2018 Dec 22;18:214. doi: 10.1186/s12935-018-0718-5. eCollection 2018.
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors. The rapid progression of PDAC results in an advanced stage of patients when diagnosed. However, the dynamic molecular mechanism underlying PDAC progression remains far from clear.
METHODS
The microarray GSE62165 containing PDAC staging samples was obtained from Gene Expression Omnibus and the differentially expressed genes (DEGs) between normal tissue and PDAC of different stages were profiled using R software, respectively. The software program Short Time-series Expression Miner was applied to cluster, compare, and visualize gene expression differences between PDAC stages. Then, function annotation and pathway enrichment of DEGs were conducted by Database for Annotation Visualization and Integrated Discovery. Further, the Cytoscape plugin DyNetViewer was applied to construct the dynamic protein-protein interaction networks and to analyze different topological variation of nodes and clusters over time. The phosphosite markers of stage-specific protein kinases were predicted by PhosphoSitePlus database. Moreover, survival analysis of candidate genes and pathways was performed by Kaplan-Meier plotter. Finally, candidate genes were validated by immunohistochemistry in PDAC tissues.
RESULTS
Compared with normal tissues, the total DEGs number for each PDAC stage were 994 (stage I), 967 (stage IIa), 965 (stage IIb), 1027 (stage III), 925 (stage IV), respectively. The stage-course gene expression analysis showed that 30 distinct expressional models were clustered. Kyoto Encyclopedia of Genes and Genomes analysis indicated that the up-regulated DEGs were commonly enriched in five fundamental pathways throughout five stages, including pathways in cancer, small cell lung cancer, ECM-receptor interaction, amoebiasis, focal adhesion. Except for amoebiasis, these pathways were associated with poor PDAC overall survival. Meanwhile, LAMA3, LAMB3, LAMC2, COL4A1 and FN1 were commonly shared by these five pathways and were unfavorable factors for prognosis. Furthermore, by constructing the stage-course dynamic protein interaction network, 45 functional molecular modules and 19 nodes were identified as featured regulators for all PDAC stages, among which the collagen family and integrins were considered as two main regulators for facilitating aggressive progression. Additionally, the clinical relevance analysis suggested that the stage IV featured nodes MLF1IP and ITGB4 were significantly correlated with shorter overall survival. Moreover, 15 stage-specific protein kinases were identified from the dynamic network and CHEK1 was particularly activated at stage IV. Experimental validation showed that MLF1IP, LAMA3 and LAMB3 were progressively increased from tumor initiation to progression.
CONCLUSIONS
Our study provided a view for a better understanding of the dynamic landscape of molecular interaction networks during PDAC progression and offered potential targets for therapeutic intervention.
背景
胰腺导管腺癌(PDAC)是最致命的实体瘤之一。PDAC的快速进展导致患者在确诊时已处于晚期。然而,PDAC进展背后的动态分子机制仍远未明确。
方法
从基因表达综合数据库获取包含PDAC分期样本的微阵列GSE62165,分别使用R软件分析不同阶段正常组织与PDAC之间的差异表达基因(DEG)。应用软件程序Short Time-series Expression Miner对PDAC各阶段之间的基因表达差异进行聚类、比较和可视化。然后,通过注释、可视化和综合发现数据库对DEG进行功能注释和通路富集分析。此外,应用Cytoscape插件DyNetViewer构建动态蛋白质-蛋白质相互作用网络,并分析节点和聚类随时间的不同拓扑变化。通过PhosphoSitePlus数据库预测阶段特异性蛋白激酶的磷酸化位点标记。此外,通过Kaplan-Meier绘图仪对候选基因和通路进行生存分析。最后,通过免疫组织化学在PDAC组织中验证候选基因。
结果
与正常组织相比,各PDAC阶段的DEG总数分别为994个(I期)、967个(IIa期)、965个(IIb期)、1027个(III期)、925个(IV期)。阶段过程基因表达分析显示聚类出30种不同的表达模型。京都基因与基因组百科全书分析表明,在五个阶段中,上调的DEG通常富集于五个基本通路,包括癌症通路、小细胞肺癌通路、细胞外基质-受体相互作用通路、阿米巴病通路、粘着斑通路。除阿米巴病通路外,这些通路均与PDAC总体生存率低相关。同时,这五个通路共同拥有LAMA3、LAMB3、LAMC2、COL4A1和FN1,且均为预后不良因素。此外,通过构建阶段过程动态蛋白质相互作用网络,鉴定出45个功能分子模块和19个节点作为所有PDAC阶段的特征性调节因子,其中胶原蛋白家族和整合素被认为是促进侵袭性进展的两个主要调节因子。此外,临床相关性分析表明,IV期特征性节点MLF1IP和ITGB4与较短的总生存期显著相关。此外,从动态网络中鉴定出15个阶段特异性蛋白激酶,CHEK1在IV期尤其被激活。实验验证表明,MLF1IP、LAMA3和LAMB3从肿瘤起始到进展逐渐增加。
结论
我们的研究为更好地理解PDAC进展过程中分子相互作用网络的动态格局提供了视角,并为治疗干预提供了潜在靶点。
相似文献
Cancer Cell Int. 2018-12-22
Asian Pac J Cancer Prev. 2015
引用本文的文献
J Gastrointest Oncol. 2024-10-31
J Cancer Res Clin Oncol. 2023-12
BMC Med Genomics. 2023-5-17
J Gastrointest Oncol. 2021-12
本文引用的文献
Bioinformatics. 2018-5-1
Nucleic Acids Res. 2017-7-3
Breast Cancer Res Treat. 2016-12